ICMR and Panacea Biotech have started Phase III clinical trials for the first time in India to develop dengue vaccine. India's indigenous tetravalent dengue vaccine, Dengiol, has been developed by Panacea Biotech. The first participant in this trial was vaccinated at Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak. The Phase III clinical trial will be conducted at 19 sites across 18 states and union territories, involving more than 10,335 healthy adult participants. Union Health Minister JP Nadda said, 'The commencement of Phase III clinical trials for India's first indigenous dengue vaccine is a significant progress in our fight against dengue. This reflects our commitment to protect our citizens from this widespread disease and underlines India's capabilities in vaccine research and development
